Chloroquine and Hydroxycholorquine - COVID-19 Clinical Trial
Current COVID-19 Clinical Trial

Chloroquine and Hydroxycholorquine

    Add a header to begin generating the table of contents

    Chloroquine has shown some promise in the treatment of COVID-19. This generic drug was approved by the FDA to treat malaria in 1949, but its origins can be traced back hundreds of years to South America. The Andean population used bark from the cinchona tree to treat shivering. The bark was brought to Europe by missionaries where it was used to treat malaria. The substance in the bark responsible for the clinical benefits was eventually isolated, creating the synthetic drug chloroquine. After decades of use, the parasite responsible for malaria has developed widespread resistance to chloroquine. With the development of new antimalarials, chloroquine is used mostly as preventative medication for malaria. 

    The relatively low cost, high availability, and anti-viral properties of chloroquine have made it a reasonable candidate to treat COVID-19. Chloroquine may slow down viruses from entering cells, interfering with infection and the rate of replication. This would give a patient’s immune system more time to fight off the virus and may also help activate the body’s immune response.  

    Early data from studies in France and China have shown that chloroquine might be successful in treating COVID-19 by preventing the worsening of pneumonia, improving lung function, and shortening the amount of time a patient is infected. This data needs to be verified with proper clinical trials, but these preliminary studies have flaws. For example, one study from France was only done with 42 participants, where only 26 patients took the medication. Of the patients that took the medication, 6 dropped out of the study, 3 of them were sent to intensive care, and one patient passed away.  

    The use of chloroquine should also be proceeded with caution because of potential toxicity which can cause an overdose with acute poisoning and death. There may also be other potential side-effects, especially when taken with other medications. In fact, different versions of chloroquine were developed to create a less toxic drug. Hydroxychloroquine, for example, is 40% less toxic than its predecessor and is FDA approved for the treatment of rheumatoid arthritis and lupus. Hydroxychloroquine is also being tested in clinical trials for the treatment of COVID-19 as it may also interfere with the infection and replication of the virus.  

    There are a number of clinical studies using chloroquine and hydroxychloroquine to treat COVID-19 taking place in multiple locations. Full clinical trials are needed to determine if the drugs are truly effective against COVID-19 and what dose is safe to use.  

    For more information on a study, or to find a location near you, please visit  

    Below is a list of some of the available clinical studies using chloroquine and hydroxychloroquine to treat COVID-19. 

    Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV) Identifier: NCT04303507 

    Description: 10,000 participants that are healthcare workers, or other individuals at significant risk of contracting COVID-19 and are at least 16 years old will be recruited onto the study. They will be randomized to prophylaxis treatment of chloroquine, or placebo. The treatment will be taken for 3 months, or until they are diagnosed with COVID-19. The study will look at the number of infections as well as the severity and duration.  

    Proactive Prophylaxis with Azithromycin and Chloroquine (ProPAC-COVID) Identifier: NCT04322396 

    Description: 226 participants diagnosed and hospitalized for with COVID-19, 18 years or older, will be randomized to placebo or hydroxychloroquine with azithromycin. This study is looking to see if the treatment can shorten hospitalization, reduce the need of ventilation, reduce the number of patients admitted to intensive care units and death.  

    Chloroquine Diphosphate for Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19) Identifier: CT04323527 

    Description: 440 participants diagnosed with COVID-19, 18 years or older, will be randomized to two different treatment arms, either a high dose of chloroquine or a low dose.  

    Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (PHYDRA) Identifier: NCT04252664 

    Description: 400 participants that are healthcare personnel and exposed to patients with COVID-19, 18 years or older, will be randomized to prophylaxis treatment with hydroxychloroquine or placebo. The study will look at the infection rate.  

    Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) Identifier: NCT04318444 

    Description: 1600 participants, 18 years or older, that were in the same household as a COVID-19 patient in New York City will be randomized to prophylaxis treatment with hydroxychloroquine or placebo. The study will look at the infection rate.

    Share this:

    Your choice regarding cookies on this site

    We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    By continuing to access this website you are giving us consent to collect cookies.

    Want to stay informed?

    With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.